KR840000378B1 - Process for preparing"mildiomycin" - Google Patents

Process for preparing"mildiomycin" Download PDF

Info

Publication number
KR840000378B1
KR840000378B1 KR1019800004563A KR800004563A KR840000378B1 KR 840000378 B1 KR840000378 B1 KR 840000378B1 KR 1019800004563 A KR1019800004563 A KR 1019800004563A KR 800004563 A KR800004563 A KR 800004563A KR 840000378 B1 KR840000378 B1 KR 840000378B1
Authority
KR
South Korea
Prior art keywords
mildiomycin
methyl
medium
culture
choline
Prior art date
Application number
KR1019800004563A
Other languages
Korean (ko)
Other versions
KR830004412A (en
Inventor
다까시 스즈끼
히데가스 사와다
쓰네도모 아사이
Original Assignee
다께다 야꾸힝 고오교오 가부시기가이샤
고니시 신베이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다께다 야꾸힝 고오교오 가부시기가이샤, 고니시 신베이 filed Critical 다께다 야꾸힝 고오교오 가부시기가이샤
Priority to KR1019800004563A priority Critical patent/KR840000378B1/en
Publication of KR830004412A publication Critical patent/KR830004412A/en
Application granted granted Critical
Publication of KR840000378B1 publication Critical patent/KR840000378B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Mildiomycin is produced by fermn. with Streptoverticillium rimofaciens. Thus, one loopful of s. rimofaciens FERM-P2549 (IFO 13592) was inoculated into 25mL medium contg. glucose 10%, Proflo 3%, corn ext. soln. 1%, NaCl 0.5%, FeSO4 0.001%, CaCO3 0.5%, and choline 3-70mM and incubated in rotary shaker (200rpm) at 28≰C fro 120hr. The broth (1 L) was filtered, treated with anion exchange chromatog., and concd. After addn. of MeOH to the conc., 1.1g mildiomycin was obtained. Mildiomycin inhibited the powder milew and has acaricidal properties.

Description

밀디오 마이신의 제조법Preparation of Mildiomycin

본 발명은 밀디오 마이신의 제조법에 관한 것이다.The present invention relates to a method for preparing Mildiomycin.

즉, 밀디오 마이신 생산능을 가진 방사선균을 배지에 배양해서 배지중에 밀디오 마이신을 생성축적시키는 밀디오 마이신의 제조법에 있어서, 배지중에 N-메틸화합물의 한 종류 또는 두 종류 이상을 존재시키는 것을 특징으로 하는 방법이다.That is, in the production method of Mildiomycin, in which a radioactive bacterium having Mildiomycin production ability is cultured in a medium to produce and accumulate Mildiomycin in the medium, the presence of one or two or more kinds of N-methyl compounds in the medium is present. It is a method characterized by.

밀디오 마이신은 항생물질 B-98891이라고 불리워져 발견된 이래, 그 성상, 구조식Mildiomycin has been called antibiotic B-98891 and has been discovered since its appearance, structural formula

Figure kpo00001
Figure kpo00001

이 명백하게 되는 한편, 그 작용특성에서, 특히 광범위한 작물의 흰가루병(powdery mildew)의 예방, 치료제 혹은 살비제로서의 효과가 주목되고 있는 항생물질이다. (특개 소 51(1976)-9718, 동 50(1975)-126892, 더 저어널 오브 안티비오틱스(The Journal of Antibiotics) 제31권, 제6호 511페이지~518페이지, 519페이지~524페이지, 1978년).On the other hand, it is an antibiotic that has been noted for its effect as a prophylactic, therapeutic or acaricide for powdery mildew in a wide range of crops. (Kiso 51 (1976) -9718, East 50 (1975) -126892, The Journal of Antibiotics, Vol. 31, No. 6, pages 511-518, pages 519-524) , 1978).

이와 같은 사실을 배경으로, 본 발명자들은 밀디오 마이신을 대량으로 또한 염가로 공급하는 것을 목적으로 해서, 그 생산조건에 대해 예의 연구를 거듭한 결과, 밀디오 마이신 생산능을 가진 방사선균을 배양할때, 배지중에 N-메틸화합물을 존재시키므로서, 현저한 양의 밀디오 마이신을 생성시킬 수 있다는 것을 발견하여, 끝내 본 발명을 완성하는 데 이르렀다.Against this backdrop, the present inventors have intensively studied the production conditions for the purpose of supplying Mildiomycin in large quantities and at low cost, and as a result, they have been cultivating radiation bacteria having Mildiomycin production capacity. At that time, it was found that a significant amount of Mildiomycin can be produced by the presence of an N-methyl compound in the medium, and finally the present invention was completed.

즉, 본 발명은 밀디오 마이신 생산능을 가진 방사선균을, N-메틸화합물을 3mM이상 함유한 배지에 배양해서, 배양물중에 밀디오 마이신을 생성 축적시키는 것을 특징으로 하는 밀디오 마이신의 제조법이다.That is, the present invention is a method for producing Mildiomycin, which comprises culturing a radiation bacterium having Mildiomycin production ability in a medium containing 3 mM or more of N-methyl compound, thereby producing and accumulating Mildiomycin in the culture. .

본 발명의 방법에 있어서 사용되는 밀디오 마이신 생산능이 있는 방사선균으로서는, 예를들어, 스트랩트버어티 실륨속(Streptoverticillium)에 속하는 방사선균, 특히 스트랩트버어티실륨 리모패시엔스(Streptoverticillium rimofaciens) FERM-P2549(IFO 13592)가 사용된다.Examples of the radiation bacterium with Mildiomycin production ability used in the method of the present invention include, for example, radiation bacteria belonging to the genus Streptoverticillium, in particular, Straptoverticillium rimofaciens FERM-. P2549 (IFO 13592) is used.

이 균은 버어지이즈 매뉴얼 오브 데터어미네티브 박테리오로지이-제7판(Bergey's Manual of Determinative Bacteriology 7th Edition)에서의 분류기준에 따른 것이며, 스태랩트마이세스 티모패시엔스(Streptomyces rimofaciens)와 동일하게 정의되었으나(특개소 50(1975)-126892), 그 후 분류기준이 개정되어, 버어지즈 매뉴얼 오브데터어미네티브 박테리오로지이-제8판(1974년)에 따라서, 본균은 스트랩트 버어티실륨속에 속해야 된다고 되었다.This bacterium is based on the classification criteria in the Burgy's Manual of Determinative Bacteriology 7th Edition and is identical to the Streptomyces rimofaciens. Although it was defined (Special Place 50 (1975) -126892), the classification criteria were subsequently revised, and according to the Burj's Manual of Determinant Bacteriologici-8th Edition (1974), the bacterium It has to belong to the inside.

(The Journal of Antibiotics, 제31권, 제6호, 511~518페이지) 또, N-메틸화합물로서는, 분자내에 1 내지 4개의 메틸기로 치환된 질소원자를 1개 이상 가진 화합물이 사용된다.(The Journal of Antibiotics, Vol. 31, No. 6, pages 511 to 518) In addition, as the N-methyl compound, a compound having one or more nitrogen atoms substituted with 1 to 4 methyl groups in a molecule is used.

그 중에서도, 예를 들면 분자내에 메틸기로 치환된 질소원자를 1개 가진 것 등이 좋으며, 특히 3개의 메틸기로 치환된 질소원자의 트리메틸암모니오기 : t2 가진 제4암모늄염이 가장 알맞다.Among them, for example, one having a nitrogen atom substituted with a methyl group in the molecule is preferable, and a fourth ammonium salt having trimethylammonio: t2 of nitrogen atoms substituted with three methyl groups is particularly suitable.

또 배지중에 >N-CH3으로 변화될 수 있는 것, 예를 들면 N,N-메틸렌비스아크릴아미드 등도 N-메틸화합물로서 사용된다. N-메틸화합물의 분자량은, 통상 50~1000 바람직하게는 90~130이다. 수용성, 비수용성에 불구하고 사용되나, 용이한 수용성인 N-메틸 화합물이 이용하기 쉽다.Also, those which can be changed to> N-CH 3 in the medium, such as N, N-methylenebisacrylamide, are also used as N-methyl compounds. The molecular weight of the N-methyl compound is usually 50 to 1000, preferably 90 to 130. Although used in spite of being water-soluble and water-insoluble, an easily water-soluble N-methyl compound is easy to use.

이와 같은 N-메틸화합물로서는, 예를들면, N-메틸산아미드, N-메틸아미노화합물, N-메틸아민, N-메틸암모늄화합물, 폴리메틸렌디아민, N,N-메틸렌비스아크릴아미드 등, N-메틸산아미드와 같은, 예를 들면, N,N-디메틸 C2-6지방족산아미드(e.g. N,N-디메틸아세트아미드 등), N-메틸알케닐카르보닐아미드(e.g. N-메틸아크릴아미드 등)와 유사한, N-메틸아미노화합물과 같은 예를 들면 모노디트리올테트라메틸요소(e.g. N-메틸요소, 1,1,3,3-테트라메틸요소 등), 디메틸아미노알코올(e,g, 2-디메틸아미노에탄올 등)과 유사한, N-메틸아민과 같은, 예를 들면, 모노디올트리메틸아민(e,g, 트리메틸아민, 디메틸아민등)과 유사한, N-메틸암모늄화합물과 같은, 예를들면 포스파티딜에탄올-모노, 디올트리메틸암모늄(e,g, 레시틴 등) 트리메틸암모늄알코올(e,g, 코린 등), 트리메틸암모늄카르복시산(e,g, 베타인 등), 알킬트리메틸암모늄(e,g, 테트라메틸암모늄 등), 에틸렌비스(트리메틸암모늄)클로라이드와 유사한 그리고 폴리메틸렌 디아민과 같은, 예를들면 에틸렌디아민, 테트라메틸렌디아민, 헥사메틸렌디아민과 같이 유효하게 사용할 수 있는 N-메틸암모늄과 특히 콜린, 베타인, 테트라메틸암모늄을 사용하였을 경우에, 좋은 결과가 얻어진다. 이들 N-메틸화합물은, 단독 또는 두 종류 이상을 혼합해서 사용하여도 지장은 없다.Examples of such N-methyl compounds include N-methyl acid amide, N-methyl amino compound, N-methylamine, N-methylammonium compound, polymethylenediamine, N, N-methylenebisacrylamide, and the like. -methyl amide such as, for example, N, N- dimethyl C 2 -6 aliphatic acid amides (eg N, N- dimethylacetamide, etc.), N- methyl-alkenyl-carbonyl amides (eg N- methylacrylamide Similar to N-methylamino compounds, for example monoditriol tetramethyl urea (eg N-methyl urea, 1,1,3,3-tetramethyl urea, etc.), dimethylaminoalcohol (e, g, Such as N-methylamine, for example N-methylammonium compound, similar to monodioltrimethylamine (e, g, trimethylamine, dimethylamine, etc.) Phosphatidylethanol-mono, dioltrimethylammonium (e, g, lecithin, etc.) trimethylammonium alcohol (e, g, corin, etc.), trimethylammonium Ethylenediamine, tetramethylene, similar to carboxylic acids (e, g, betaine, etc.), alkyltrimethylammonium (e, g, tetramethylammonium, etc.), ethylenebis (trimethylammonium) chloride and like polymethylene diamine Good results are obtained when N-methylammonium, which can be effectively used such as diamine and hexamethylenediamine, and especially choline, betaine and tetramethylammonium are used. These N-methyl compounds may be used alone or in combination of two or more.

또 N-메틸화합물의 함유물, 예를들면 베타인을 함유한 사탕무우당밀, 레시틴을 함유한 대두가루 또는 콜린과 레시틴을 함유하은 계란 등을 다량 배지중에 첨가하고, N-메틸화합물로서 3mM 이상 함유시키는 방법도 본 특허의 청구범위에 함유된다.Also, N-methyl compounds, such as betaine molasses containing betaine, soy flour containing lecithin, or eggs containing choline and lecithin are added to the medium, and the content of N-methyl compound is 3 mM or more. The method of making is also included in the claims of the present patent.

배지에 함유되는 N-메틸화합물의 농도는, 사용하는 미생물의 발육을 억제하지 않는 범위에서 적의 선택하면 되고, 통상 3mM 이상 함유시켜진다.What is necessary is just to select suitably the density | concentration of the N-methyl compound contained in a culture medium in the range which does not suppress the growth of the microorganism to be used, and it is contained normally 3mM or more.

바람직하게는 4mM 내지 200mM, 더욱 바람직하게는 7~50mM의 첨가가 효과적이며, 200mM를 초과하면 효과의 진전율이 둔화한다. 또, N-메틸화합물을 함유하는 천연물의 첨가량은 함유되는 N-메틸화합물의 농도가 전술한 범위가 되도록 선택되면 좋으나, 종래의 첨가량을 초과하면 다량을 사용하게 되므로, 천연물의 단독첨가로는 다른 성분의 영향에 따라 미생물의 발육이 현저하게 영향을 받아, 밀디오 마이신의 생산이 저해될 경우도 있고, 그 경우에는 N-메틸화합물을 병용하는 것이 좋다.Preferably, the addition of 4 mM to 200 mM, more preferably 7 to 50 mM, is effective, and when it exceeds 200 mM, the progress of the effect is slowed down. In addition, the addition amount of the natural product containing the N-methyl compound may be selected so that the concentration of the N-methyl compound contained may be in the above-mentioned range, but when the amount of the conventional addition exceeds the conventional amount, a large amount is used. Depending on the effect of the components, the growth of microorganisms is remarkably affected, and the production of Mildiomycin may be inhibited. In that case, it is preferable to use an N-methyl compound in combination.

또 이들의 N-메틸화합물을 배지에 함유시키는 시기로서는, 배지에 미생물을 접종하기 이전에 첨가하는 것이 가장 용이하고 또한 효과적인 방법이지만 배양하는 동안에 적의 첨가할 수 있다.In addition, as the timing for incorporating these N-methyl compounds into the medium, it is the easiest and most effective method to add the medium before inoculating the microorganisms, but it can be appropriately added during the culture.

또, 배양에 사용되는 배지의 탄소원으로서는, 예를들면 전분, 덱스트린, 포도당, 맥아당, 설탕, 소트비톨등 외에 당밀, 코온시럽, 물엿 등에 사용되는 미생물을 이용할 수 있는 당류외에, 예를들면 아세트산, 숙신산 등의 유기산이나 유지등도 사용할 수 있다.Moreover, as a carbon source of the medium used for cultivation, for example, starch, dextrin, glucose, maltose, sugar, sorbitol and the like, in addition to sugars that can use microorganisms used in molasses, coon syrup, starch syrup, for example acetic acid, Organic acids such as succinic acid and fats and oils can also be used.

질소원으로서는 각종의 암모늄염, 초산염이나 요소외에, 효모추출물, 카세인, 고기즙, 면실박, 옥수수침지액, 대두박 등의 유기천연물 등도 사용할 수 있다.As the nitrogen source, in addition to various ammonium salts, acetates, and urea, yeast extract, casein, meat juice, cottonseed foil, corn steep liquor, and organic natural substances such as soybean meal can be used.

또한 무기염류로서는, 예를들어 철, 마그네슘, 망간, 코발트, 동, 나트륨, 칼륨, 칼슘, 아연 등의 염류가 알맞게 필요에 따라서 사용된다. 사용할 미생물이 아미노산, 비타민, 핵산염기 등의 특정한 영양물을 요구하는 경우에는 그것들을 알맞게 첨가할 수 있다.As the inorganic salts, for example, salts such as iron, magnesium, manganese, cobalt, copper, sodium, potassium, calcium, and zinc are suitably used as necessary. If the microorganisms to be used require specific nutrients such as amino acids, vitamins and nucleic acid bases, they can be added as appropriate.

배양은 청치배양법, 통기교반배양법, 진탕배양법 등이 적용되나, 통상 통기교반배양법에 의하는 것이 유리하다.Cultivation is applied to the chungchi culture method, aeration stirring culture method, shaking culture method, etc., but usually by aeration stirring culture method is advantageous.

배양온도로서는 20℃ 내지 40℃, 바람직하게는 24℃ 내지 34℃, 또 배치의 액체성으로서는, 통상 pH 4 내지 9의 범위로 유지되는 것이 바람직하고, 이를 위해서는, 예를들어 가성알칼리나 암모니아수, 혹은 황산, 염산 등의 희석수용액을 가지고 알맞게 보정하면서 배양하거나, 탄산칼슘, 탄산소오다 등의 알칼리염류 등을 배지에 첨가하여도 된다. 배양시간은, 충분히 밀디오 마이신이 생산될 때까지 배양하면 목적을 달성할 수 있으나, 통상 4~12일간 사이에서 최대의 수량을 얻을 수 있다.As culture temperature, it is 20 degreeC-40 degreeC, Preferably it is 24 degreeC-34 degreeC, As a liquidity of a batch, it is preferable to maintain normally in the range of pH 4-9, For this, for example, caustic alkali, ammonia water, Alternatively, the mixture may be cultured with a dilute aqueous solution such as sulfuric acid or hydrochloric acid while correcting, or an alkali salt such as calcium carbonate or sodium carbonate may be added to the medium. The incubation time can be achieved by culturing until the production of Mildiomycin sufficiently, the maximum yield can usually be obtained between 4 to 12 days.

이와 같이 해서 얻어진 배양물에서 밀디오 마이신을 분리, 채취할 필요가 있을 경우에는, 일반적으로 염기성 수용성 항생물질의 분리수단으로서 사용되는 공지의 방법이 알맞게 적용된다.When it is necessary to isolate and extract Mildiomycin from the culture thus obtained, a known method generally used as a means for separating basic water-soluble antibiotics is suitably applied.

예를들면, 여과 또는 원신분리 등의 방법으로 균체 및 배양물중의 불용성분을 제거한 후, 활성탄 혹은 흡착성수지와 접촉시켜서 밀디오 마이신을 흡착시켜, 이것을 함수유기용제, 염 혹은 산함유수, 완충액 등을 사용해서 용리할 수 있다.For example, the insoluble components in the cells and cultures are removed by filtration or centrifugation, and then contacted with activated carbon or an adsorbent resin to adsorb Mildiomycin, which is a water-containing organic solvent, salt or acid-containing water, or buffer solution. And the like can be eluted.

또, 본 항생물질은 염기성물질이므로 양이온교환수지에 잘 흡수되고, 이것을 적당한 산, 알칼리 혹은 완충액에 의해 용리하는 것도 가능하다. 이러한 방법을 필요에 따라서 알맞게 선택, 조합해서 행한 후 농축, 결정하면, 밀디오 마이신을 얻을 수 있다.In addition, since the antibiotic is a basic substance, it is well absorbed by the cation exchange resin, and it can be eluted with a suitable acid, alkali or buffer solution. Mildiomycin can be obtained by selecting, combining, and concentrating these methods suitably as needed.

이렇게 해서 얻어지는 밀디오 마이신은, 식물용 살균살비제의 유효성분으로서 안전하게 사용할 수 있다. (미국특허 4,007,267, 영국특허 1,507,193)Mildiomycin obtained in this way can be used safely as an active ingredient of plant fungicide. (U.S. Patent 4,007,267, United Kingdom Patent 1,507,193)

이하 실시예를 사용해서 본 발명의 내용을 더욱 구체적으로 설명하는데, 본 예를 가지고, 본 발명의 내용을 규제하는 것이 아니다.Although the content of this invention is demonstrated further more concretely using an Example below, with this example, the content of this invention is not restrict | limited.

[실시예 1]Example 1

(1) 포도당 10%, 면실배아분(상품명 프로프로, Traderoil Mill Co. U.S.A.) 3% 옥수수침지액 1%, 식염 0.5%, 제1황산철 0.001%, 탄산칼슘 0.5%로 된 배지 25ml에 콜린을 제1표에 표시한 농도가 되도록 가한 후, 20% 가성소오다 수용액을 적하하므로서, pH를 7.0으로 조정한다.(1) 10% glucose, cottonseed germ meal (trade name Propro, Traderoil Mill Co. USA) 3% corn steep liquor 1%, salt 0.5%, ferrous sulfate sulfate 0.001%, calcium carbonate 0.5% Is added to the concentration shown in the first table, and then the pH is adjusted to 7.0 by dropwise adding 20% aqueous sodium hydroxide solution.

다음에 이것을 감균하여, 이들에 스트랩트버어티실륨 리모패시엔스 FERM-P2549(IFO 13592)의 사면배양물 1백금이(Platinum loop)를 접종하여, 200rpm의 회전진탕기상에서 28℃로 120시간 배양하였다.Next, it was sterilized and inoculated with a platinum loop of a culture medium of FERM-P2549 (IFO 13592), and incubated at 28 ° C. for 120 hours on a 200 rpm rotating shaker. It was.

배양액중의 밀디오 마이신을 공지의 방법(The Journal of Antibiotics, 제31권, 제6호, 519~524페이지, 1978년)에 따라서 정량한 결과, 제1표에 표시한 결과를 얻었다.Mildiomycin in the culture was quantified according to a known method (The Journal of Antibiotics, Vol. 31, No. 6, pages 519-524, 1978). The results shown in Table 1 were obtained.

[제 1 표][Table 1]

Figure kpo00002
Figure kpo00002

(2) 상기(1)에 있어서, 콜린 14mM 첨가한 배지를 사용한 배양물 1l를 모여서, 원심분리에 의해서, 표면에 떠 오른 액을 얻어서, 이것을 이온교환수지 앰버라이트(Amberlite) IRC-50(H+-형)(Rohm & Haas Co. U.S.A.제) 500ml를 충전한 컬럼에 통액하였다.(2) In the above (1), 1 l of the culture using a medium added with choline 14 mM was collected and centrifuged to obtain a liquid floating on the surface, which was obtained by ion exchange resin Amberlite IRC-50 (H). + -Form) (made by Rohm & Haas Co. USA) was passed through a packed column.

컬럼을 수세한 후, 0.5% 암모니아수 500ml를 사용해서 용출하고, 황성획분을 크로마토그래피용 활성탄(다께다야꾸힝제) 50ml의 컬럼에 통액, 흡착시켰다.The column was washed with water, eluted with 500 ml of 0.5% ammonia water, and the sulfur fraction was passed through a column of 50 ml of activated carbon for chromatography (Tadaya quenching agent) and adsorbed.

아세톤-물(3 : 7)의 혼합용매 250ml를 사용해서 용출된 활성획분을 모아서 농축하고, 농축액에 아세톤을 적하해서, 조밀디오마이신을 석출시켰다.250 ml of acetone-water (3: 7) mixed solvent was used to collect and concentrate the eluted active fractions, and acetone was added dropwise to the concentrate to precipitate dense dimycin.

조분말 1.3g을 물에 녹여서, 암바라이트CG-50(H+-형)(Rohm &Hass Co. U.S.A제) 25ml의 컬럼에 통액한 뒤, 컬럼을 10ml의 물로 세정하고, 이어서 0.5% 암모니아수 250ml를 사용해서 용출하였다.1.3 g of crude powder was dissolved in water and passed through a 25 ml column of Ambarite CG-50 (H + -) (manufactured by Rohm & Hass Co. USA), and then the column was washed with 10 ml of water, followed by 250 ml of 0.5% ammonia water. Eluted using.

활성획분을 모아서, 활성탄 50ml의 컬럼에 통액해서 흡착시켜, 아세톤-0.1N포름산(2 : 8) 250ml를 사용해서 분획용출하고, 활성획분을 농축하였다.The active fractions were collected, passed through a column of 50 ml of activated carbon, adsorbed, fractional eluted with 250 ml of acetone-0.1N formic acid (2: 8), and the active fractions were concentrated.

농축액에 메탄올을 가해서 밀디오마이신을 석출시켰다.Methanol was added to the concentrate to precipitate Mildiomycin.

이것을 감압하에 건조해서, 1.1g의 밀디오마이신 포름산염을 얻었다 : 이것의 이화학적성질중, 융점, 선광도(Cl,O,H2O 및 Cl,O,0.1N HCl에서의

Figure kpo00003
271nm 및 280nm에서의 자외선부 흡광도계수는 완전히 문헌에 기재된 값과 일치되었다. (The Journal of Antibiotics, 제31권, 제6호 523페이지, 1978년)It was dried under reduced pressure to obtain 1.1 g of Mildiomycin Formate: in its physicochemical properties, at its melting point, its fluorescence (Cl, O, H 2 O and Cl, O, 0.1 N HCl).
Figure kpo00003
The UV absorbance coefficients at 271 nm and 280 nm were in full agreement with the values described in the literature. (The Journal of Antibiotics, Vol. 31, No. 6, page 523, 1978).

[실시예 2]Example 2

실시예 1과 마찬가지의 방법으로, 배지에 콜린대신에 제2표에 표시한 각종의 N-메틸화합물을 7mM의 농도로 첨가해서 배양, 정량한 결과, 제2표에 표시한 결과를 얻었다.In the same manner as in Example 1, various N-methyl compounds shown in Table 2 instead of choline were added to the medium at a concentration of 7 mM to culture and quantitatively obtain the results shown in Table 2.

[제 2 표][Table 2]

Figure kpo00004
Figure kpo00004

[실시예 3]Example 3

실시예 1과 마찬가지의 방법으로, 배지에 콜린대신에 페타인을 아래 표의 각종의 농도가 되도록 가해서 배양, 정량한 결과, 제3표에 표시한 결과를 얻었다.In the same manner as in Example 1, petane was added to the medium instead of choline to have various concentrations in the table below, followed by culturing and quantification, and the results shown in Table 3 were obtained.

[제 3 표][Table 3]

Figure kpo00005
Figure kpo00005

[실시예 4]Example 4

실시예 1과 마찬가지인 방법으로, 배지에 콜린과 테트라메틸암모늄 염산염을 조합해서, 아래 표의 각종의 농도가 되도록 혼합첨가하여, 배양, 정량한 결과, 제4표에 표시한 결과를 얻었다.In the same manner as in Example 1, choline and tetramethylammonium hydrochloride were combined in the medium, mixed and added so as to have various concentrations in the table below, and cultured and quantified, and the results shown in Table 4 were obtained.

[제 4 표][Table 4]

Figure kpo00006
Figure kpo00006

[실시예 5]Example 5

실시예 1의 방법에 있어서, 콜린대신에 1,1,3,3-테트라메틸요소를 사용하고 또한 배양액에 첨가하는시기를 아래 표와 같이 바꾸어서 첨가한 외는, 마찬가지의 방법으로 배양, 정량한 결과를 제5표에 표시하였다.In the method of Example 1, except that choline was used instead of 1,1,3,3-tetramethylurea and the time of addition to the culture medium was changed as shown in the table below, and the result was incubated and quantified by the same method. Is shown in Table 5.

첨가량은 배양액중 7mM로 하였다.The addition amount was 7 mM in the culture solution.

[제5표][Table 5]

Figure kpo00007
Figure kpo00007

Claims (1)

스트랩트 버어티실륨속에 속하는 밀디오마이신 생산균을. N-메틸화합물을 3mM 이상 함유하는 배지에서 배양해서, 배양물중에 밀디오마이신을 생성축적시키는 것을 특징으로 하는 밀디오 마이신의 제조법.Mildiomycin-producing bacteria belonging to the strap variety silium. A method for producing Mildiomycin, characterized by culturing N-methyl compound in a medium containing 3 mM or more, thereby producing and accumulating Mildiomycin in the culture.
KR1019800004563A 1980-11-28 1980-11-28 Process for preparing"mildiomycin" KR840000378B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019800004563A KR840000378B1 (en) 1980-11-28 1980-11-28 Process for preparing"mildiomycin"

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019800004563A KR840000378B1 (en) 1980-11-28 1980-11-28 Process for preparing"mildiomycin"

Publications (2)

Publication Number Publication Date
KR830004412A KR830004412A (en) 1983-07-13
KR840000378B1 true KR840000378B1 (en) 1984-03-27

Family

ID=19218372

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019800004563A KR840000378B1 (en) 1980-11-28 1980-11-28 Process for preparing"mildiomycin"

Country Status (1)

Country Link
KR (1) KR840000378B1 (en)

Also Published As

Publication number Publication date
KR830004412A (en) 1983-07-13

Similar Documents

Publication Publication Date Title
US2595499A (en) Process for production of vitamin b12
DE3750523T2 (en) Process for the preparation of L-2-amino-4- (hydroxymethylphosphinyl) butyric acid.
DE60318133T2 (en) Anhydrous L-lysine as a main ingredient containing granules
EP0182315B1 (en) Novel antibiotic nk84-0218 pharmaceutical compositions containing it and process for the production of the same
KR870001373B1 (en) Process for preparing antibiotic bmg 162-af2
CH634599A5 (en) METHOD FOR PRODUCING NEW ANTIBIOTICS OF thienamycin SERIES.
US5169767A (en) Method of producing trehalose
DE2757980C2 (en)
KR840000378B1 (en) Process for preparing"mildiomycin"
US4334022A (en) Method for producing mildiomycin
JPH0226957B2 (en)
US3000793A (en) Production of cobalamins
EP0236894B1 (en) Efomycine G, its preparation and its use as an animal growth promotor
JPH022589B2 (en)
US2985564A (en) Production of puromycin
JP3067183B2 (en) Method for producing FR900506 substance
DE69633619T2 (en) PROCESS FOR THE PREPARATION OF L-2-AMINOADIPIC ACID
DE2318650C2 (en) Fermentative production of deacetylcephalosporin C
DE3511753A1 (en) USE OF EFOMYCINES AS A GROWTH SUPPORT, EFOMYCINE AND THEIR PRODUCTION
US4132779A (en) Antibiotic BL580 Zeta and use thereof as anticoccidial agent
US2947666A (en) Amino acids and process
EP0662145B1 (en) Process for the selective increase of production of antibiotic ge 2270 factor a
KR910000454B1 (en) Novel microorganism streptomyces sp kccb2
KR940004000B1 (en) Production of mildiomycin
US2960446A (en) Process for preparing hydroxybenzimidazole by fermentation